Glenview Trust Co purchased a new stake in Danaher Corporation (NYSE:DHR - Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 10,662 shares of the conglomerate's stock, valued at approximately $2,031,000.
Several other large investors have also bought and sold shares of the stock. EP Wealth Advisors LLC bought a new stake in Danaher during the 2nd quarter worth approximately $3,807,000. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Danaher by 303.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 248,020 shares of the conglomerate's stock worth $56,777,000 after purchasing an additional 186,584 shares during the period. Puzo Michael J purchased a new stake in shares of Danaher in the second quarter worth $8,624,000. Madison Asset Management LLC bought a new stake in Danaher during the second quarter valued at $85,451,000. Finally, Legal & General Group Plc grew its position in Danaher by 1.0% during the fourth quarter. Legal & General Group Plc now owns 4,495,287 shares of the conglomerate's stock worth $1,029,061,000 after buying an additional 43,169 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.
Analyst Ratings Changes
Several analysts have weighed in on DHR shares. Wells Fargo & Company lowered their price target on Danaher from $212.00 to $195.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 22nd. Guggenheim lowered their target price on shares of Danaher from $235.00 to $200.00 and set a "buy" rating on the stock in a research note on Wednesday, July 22nd. DZ Bank started coverage on shares of Danaher in a research report on Wednesday, June 3rd. They set a "buy" rating and a $210.00 target price for the company. Citigroup started coverage on shares of Danaher in a research note on Tuesday, May 26th. They issued a "buy" rating and a $230.00 price target for the company. Finally, Piper Sandler assumed coverage on shares of Danaher in a research report on Thursday, June 11th. They set a "neutral" rating and a $200.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $228.91.
Get Our Latest Analysis on DHR
Danaher Stock Up 0.3%
DHR opened at $216.41 on Friday. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The company has a current ratio of 1.65, a quick ratio of 1.25 and a debt-to-equity ratio of 0.48. The business's 50-day moving average price is $199.46 and its 200-day moving average price is $192.52. The company has a market cap of $152.13 billion, a P/E ratio of 38.44, a P/E/G ratio of 2.69 and a beta of 0.78.
Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a return on equity of 11.04% and a net margin of 15.95%.The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period last year, the company earned $0.77 EPS. Danaher's revenue for the quarter was up 5.5% compared to the same quarter last year. On average, equities analysts expect that Danaher Corporation will post 8.53 EPS for the current year.
About Danaher
(
Free Report)
Danaher Corporation NYSE: DHR is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.
Products and services in Danaher's portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
